samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PHASTAR Announces Investment by Charterhouse Capital Partners

PHASTAR

Funding will Support Expansion of Statistics and Data Science Services and Geographic Reach


London, UK and Durham, NC – 5 January 2021 – PHASTAR, a specialist biometrics clinical research organization (CRO) for clinical trials, announces an investment made by Charterhouse Capital Partners LLP, a long-established European private equity firm, which will support PHASTAR’s growth in biometrics and geographic expansion. Charterhouse is making its investment in partnership with PHASTAR’s Founder and CEO Kevin Kane, who remains a significant shareholder in the business. Kevin and the existing management team will continue to run, manage and operate the business on a day-to-day basis.

"PHASTAR's partnership with Charterhouse is a significant next step in our planned growth strategy," said Kane. "With a new office opening in China our global footprint will widen to include the UK, Europe, Africa, the U.S. and Asia, giving us an opportunity to better serve our clients anywhere in the world. We are extremely grateful for the support our clients and team members have shown over the past 13 years. We anticipate that support will continue to cement PHASTAR’s position as the partner of choice for pharmaceutical companies in their critical statistical and data science projects in the years ahead," he added.

As part of the transaction, Dr. Nick Edwards, MD will become Non-Executive Chair of PHASTAR. Dr. Edwards is currently the Chairman of the Board of Directors at Prescient Healthcare Group. Dr. Edwards brings to PHASTAR wide-ranging industry experience in the medical and pharmaceutical industries as a medical doctor and also as co-founder of Kinapse life sciences consultancy. Additionally, he served as lead partner in Accenture’s Pharmaceutical R&D Practice. With his exceptional breadth of industry knowledge, Dr. Edwards will provide significant contributions to strategic business discussions in support of PHASTAR’s future planning and provide a key link between PHASTAR’s business and Charterhouse.

"PHASTAR is a superb provider of statistical support to its clients and operates in a very attractive industry, supported by numerous long-term growth drivers. The company has an enviable reputation, among both pharmaceutical companies and individual statisticians, and is an excellent fit for our firm's investment strategy. We have been particularly impressed by the relentless focus on quality and service, which is core to PHASTAR’s culture. We look forward to working with Kevin and the entire PHASTAR team to leverage the enormous opportunity for further growth during the coming years," commented James Cocker, Partner at Charterhouse.

Edgemont Partners acted as advisors to PHASTAR and Charterhouse was advised by Results Healthcare.

About PHASTAR

PHASTAR is a global specialist biometrics CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP style arrangements and preferred partnerships. PHASTAR’s number one priority is to ensure that the work produced is of the highest quality. Every project PHASTAR undertakes utilizes unique internal processes, designed to ensure optimal quality. All PHASTAR’s statistical, programming, data management and data science staff are trained in the “PHASTAR Discipline” - an in-house approach to data analysis and collection. This comprises a set of common sense (but commonly ignored) principles that, if followed, guarantee error free outcomes. The “PHASTAR Discipline” also includes a series of intranet-based checklists highlighting potential pitfalls and points-to-consider when conducting clinical trials, enabling over 3,700 years of combined technical knowledge to be shared across the company. As the largest UK headquartered biometrics CRO, PHASTAR has 12 office locations worldwide (United States, United Kingdom, Australia, Germany, Kenya and Japan). For further information on PHASTAR contact tellmemore@phastar.com.

About Charterhouse Capital Partners LLP


Charterhouse is one of the longest established private equity firms operating in Europe. The firm connects expertise and capital, collaborating with ambitious management teams to drive transformational change.

Charterhouse has a selective, conviction-led approach to investing in high-quality mid-market European companies across the Services, Healthcare, Specialised Industrials and Consumer sectors. It targets transactions with an enterprise value of between €75m and €1.5bn.

Charterhouse’s international team works in an integrated and flexible manner, without internal silos, from one main office in London. This allows the firm to work in true partnership with management and combine the skills, knowledge and experience of its entire team to help build successful businesses over the long term.

www.charterhouse.co.uk
phone +44 (0)20 7183 7062
email tellmemore@phastar.com
web www.phastar.com
email Unit 2, 2A Bollo Ln, Chiswick, London W4 5LE
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Thermo Fisher Scientific launches online 2D-LC systems to characterize complex samples

GERMERING, Germany – (February 17, 2021) - Thermo Scientific Vanquish Online 2D-Liquid Chromatography (LC) Systems offer a robust and flexible platform for pharmaceutical/biopharmaceutical R&D, food safety, environmental testing, omics and polymer analysis scientists to characterize complex samples in-depth with the highest confidence.
More info >>


White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement